Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses.
Clinical studies over the past several years have reported that metastasis-free survival times in humans and dogs with osteosarcoma are significantly increased in patients that develop chronic bacterial osteomyelitis at their surgical site. However, the immunological mechanism by which osteomyelitis may suppress tumor growth has not been investigated. Therefore, we used a mouse model of osteomyelitis to assess the effects of bone infection on innate immunity and tumor growth. A chronic Staphylococcal osteomyelitis model was established in C3H mice and the effects of infection on tumor growth of syngeneic DLM8 osteosarcoma were assessed. The effects of infection on tumor angiogenesis and innate immunity, including NK cell and monocyte responses, were assessed. We found that osteomyelitis significantly inhibited the growth of tumors in mice, and that the effect was independent of the infecting bacterial type, tumor type, or mouse strain. Depletion of NK cells or monocytes reversed the antitumor activity elicited by infection. Moreover, infected mice had a significant increase in circulating monocytes and numbers of tumor associated macrophages. Infection suppressed tumor angiogenesis but did not affect the numbers of circulating endothelial cells. Therefore, we concluded that chronic localized bacterial infection could elicit significant systemic antitumor activity dependent on NK cells and macrophages.
Sottnik
Joseph L
JL
Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Ft. Collins, 80523, USA. jsottnik@rams.colostate.edu
U'Ren
Lance W
LW
Thamm
Douglas H
DH
Withrow
Stephen J
SJ
Dow
Steven W
SW
D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D009000:Monocytes / Q000276:immunology; D009369:Neoplasms; D009389:Neovascularization, Pathologic; D010019:Osteomyelitis / Q000150:complications*; D012516:Osteosarcoma / Q000150:complications* / Q000276:immunology* / Q000473:pathology; D013203:Staphylococcal Infections / Q000150:complications*
Exp Hematol. 2006 Oct;34(10):1393-402
16982332
N Engl J Med. 1986 Dec 25;315(26):1650-9
3537791
J Antimicrob Chemother. 2002 Aug;50(2):289-92
12161415
Nat Rev Cancer. 2009 Jan;9(1):64-71
19104515
Int J Cancer. 2008 Feb 15;122(4):930-5
17960612
J Clin Invest. 1995 Dec;96(6):2578-82
8675621
J Leukoc Biol. 2007 Aug;82(2):244-52
17475785
J Immunother (1991). 1992 Jul;12(1):13-8
1637780
Immunol Cell Biol. 2009 Jan;87(1):30-8
19048016
J Clin Invest. 1996 Jun 15;97(12):2722-7
8675682
Cell Cycle. 2009 Mar 15;8(6):870-5
19221501
Clin Cancer Res. 2005 Jul 1;11(13):4827-34
16000580
J Leukoc Biol. 2007 May;81(5):1224-35
17311932
Clin Orthop Relat Res. 2008 Jun;466(6):1285-91
18421536
Immunobiology. 2006;211(6-8):609-18
16920499
J Exp Med. 2006 Mar 20;203(3):583-97
16492803
Immunity. 2003 Jul;19(1):71-82
12871640
Nat Rev Immunol. 2008 Dec;8(12):958-69
19029990
Cancer Sci. 2008 Aug;99(8):1595-602
18754872
J Immunol. 2004 Feb 1;172(3):1407-13
14734716
Mol Cancer Ther. 2008 Apr;7(4):788-99
18375821
J Immunol. 2004 Apr 1;172(7):4410-7
15034056
Cancer Lett. 2008 Aug 28;267(2):204-15
18448242
Curr Treat Options Oncol. 2008 Feb;9(1):67-80
18449804
Nat Rev Cancer. 2008 Feb;8(2):147-56
18202698
Nat Rev Cancer. 2006 Nov;6(11):835-45
17036040
Int J Cancer. 1998 May 4;76(3):418-22
9579581
J Immunol. 2001 May 15;166(10):5878-81
11342601
J Immunol. 1999 Aug 1;163(3):1552-61
10415059
Cancer Res. 2006 Jan 15;66(2):605-12
16423985
Trends Immunol. 2002 Nov;23(11):549-55
12401408
J Cell Biol. 1987 Mar;104(3):689-96
3102503
Cancer Immunol Immunother. 2009 May;58(5):769-75
18633610
Ann Surg Oncol. 2005 Dec;12(12):1073-83
16252138
Curr Oncol Rep. 2008 Jul;10(4):350-8
18778562
Bioessays. 2006 Jan;28(1):84-94
16369949
J Immunol Methods. 1994 Sep 14;174(1-2):83-93
8083541
Immunobiology. 1992 Jun;185(1):11-9
1398738
Cancer Biol Ther. 2003 Nov-Dec;2(6):687-93
14688478
Gene Ther. 2007 Nov;14(22):1573-86
17898797
Anticancer Res. 2007 Jan-Feb;27(1A):155-64
17352227
Cell Tissue Res. 1984;238(2):355-8
6239690
Gene Ther. 2009 Mar;16(3):329-39
19177133
Ann Surg. 1937 Jan;105(1):152-5
17856903
J Korean Med Sci. 2007 Sep;22 Suppl:S38-46
17923753
Br J Cancer. 2006 Aug 7;95(3):272-81
16832418
Cytokine Growth Factor Rev. 2003 Feb;14(1):67-77
12485620
Ann Surg Oncol. 2009 Jan;16(1):147-51
18979137
Nat Rev Cancer. 2008 Aug;8(8):618-31
18633355
J Invest Dermatol. 2007 Aug;127(8):2031-41
17460736
Ann Surg Oncol. 2007 Oct;14(10):2887-95
17653803
J Exp Med. 2007 May 14;204(5):1057-69
17485518
Blood. 1995 May 15;85(10):2910-7
7742551
J Immunol. 2009 Mar 1;182(5):3105-11
19234207
Cancer Immunol Immunother. 2007 Aug;56(8):1265-74
17219148